Financial Performance - The company's revenue for Q1 2023 was ¥157,152,422.97, representing a 30.02% increase compared to ¥120,869,514.08 in the same period last year[5] - Net profit attributable to shareholders reached ¥25,325,308.14, a significant increase of 159.52% from ¥9,758,558.93 year-on-year[5] - Basic earnings per share rose to ¥0.42, up 90.91% from ¥0.22 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 157,152,422.97, an increase of 30.0% compared to CNY 120,869,514.08 in Q1 2022[21] - Net profit for Q1 2023 reached CNY 25,325,308.14, representing a significant increase of 159.5% compared to CNY 9,758,558.93 in Q1 2022[22] - Earnings per share for Q1 2023 were CNY 0.42 (basic) and CNY 0.41 (diluted), compared to CNY 0.22 for both in Q1 2022[23] Cash Flow and Assets - The net cash flow from operating activities improved to ¥17,660,682.50, a turnaround from a negative cash flow of -¥22,515,151.37 in the previous year, marking a 178.44% increase[5] - Cash and cash equivalents at the end of the reporting period amounted to CNY 692.60 million, up from CNY 677.45 million at the beginning of the year[17] - The net cash flow from operating activities for the current period is CNY 17,660,682.50, compared to a loss of CNY 22,515,151.37 in the previous period, indicating a significant turnaround[26] - The ending balance of cash and cash equivalents was CNY 692,603,148.66, significantly higher than CNY 110,562,574.87 at the end of the previous period[26] Liabilities and Equity - Total assets at the end of the reporting period were ¥1,198,058,658.18, reflecting a 3.22% increase from ¥1,160,719,180.61 at the end of the previous year[5] - The company’s total liabilities decreased significantly, with accounts payable dropping by 85.70% to ¥1,393,710.82 from ¥9,747,127.73[10] - Total liabilities for Q1 2023 were CNY 217,053,366.30, slightly up from CNY 208,751,387.51 in the previous year[19] - The weighted average return on equity decreased to 2.62%, down from 4.17% in the previous year[5] Income and Investments - The company reported a significant increase in other income, totaling ¥7,504,421.66, which is a 356.94% rise compared to ¥1,642,329.68 in the previous year[10] - The company’s investment income surged to ¥865,047.41, a 300.13% increase from a loss of -¥432,245.20 in the same period last year[10] - The company reported a significant increase in investment income of CNY 865,047.41 compared to a loss of CNY 432,245.20 in Q1 2022[22] Operational Highlights - As of the end of the reporting period, the company had a total of 3,896 employees, with over 3,700 being professional staff[14] - The company has served nearly 800 clinical trial institutions, covering more than 1,300 institutions nationwide[14] - The company has undertaken over 2,500 international and domestic SMO projects, with 1,505 projects currently in execution[14] Research and Development - Research and development expenses for Q1 2023 were CNY 6,857,112.53, a slight increase from CNY 6,800,070.53 in the same period last year[22] Future Plans - The company plans to continue expanding its market presence and investing in new product development to sustain growth[20] Governance - The company successfully completed the election of its third board of directors and supervisory board on March 16, 2023[15] Audit Status - The company has not undergone an audit for the first quarter report[27]

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）《2022 年年 度报告》及摘要已于 2023 年 4 月 27 日披露在巨潮资讯网，为方便投资者进一步 了解公司经营情况，公司将于 2023 年 5 月 9 日（星期二）15:00-17:00 举行 2022 年度报告业绩说明会。现将具体情况公告如下： 一、召开情况 1、召开时间：2023 年 5 月 9 日（星期二）15:00-17:00； 2 、 召 开 地 点 ： 上海证券报·中国证券网路演中心： https://roadshow.cnstock.com/ 3、召开方式：网络文字互动 证券代码：301257 证券简称：普蕊斯 公告编号：2023-025 普蕊斯（上海）医药科技开发股份有限公司 关于举行 2022 年度报告业绩说明会的公告 三、投资者提问征集方式 为充分尊重投资者、提升交流的针对性，公司就 2022 年度报告业绩说明会 提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 9 日（星期二）15:00 ...

证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 编号：2022-007 | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------|-------------------------------------------------------------------------|---------------------------------------|------------------|-------|-------|------------------|--------| | | | | | | | | | | | 特定对象调研 □分析师会议 | | | | | | | | | □媒体采访 □业绩说明会 | | | | | | | | 投资者关系 | □新闻发布会 | □路演活动 | | | | | | | 活动类别 | □现场参观 □券商策略会 | | | | | | | | | □其他 | （请文字说明其他活动内容） | | | | | | | ...

Group 1: Company Overview - Prasis was established in 2013, focusing on clinical research and development services for pharmaceutical and medical device companies [2] - As of June 30, 2022, the company has undertaken over 2,100 clinical trial projects [2] - The company has facilitated the launch of over 90 innovative drugs or medical devices in domestic and international markets [3] Group 2: Market Position and Barriers - The SMO industry has significant entry barriers, including client access barriers and scale barriers related to institutional coverage [3] - As of June 30, 2022, the company covers over 1,100 clinical trial institutions across more than 160 cities in China [3] - The company employs over 3,400 professionals, ensuring a stable and professional talent pool for project execution [4] Group 3: Financial Performance - In the first half of 2022, the company signed new contracts worth 487.33 million CNY, a year-on-year increase of 57.77% [5] - Clinical trial project cycles typically last 2-3 years or longer, with revenue recognition not being linear due to various influencing factors [5] Group 4: Revenue Recognition and Payment Terms - The company uses the input method for revenue recognition, confirming revenue based on incurred costs until progress can be reasonably determined [5] - Payment milestones are defined in contracts, including: - 0% to 30% upon contract signing - 15% to 45% upon center initiation - 60% to 80% upon subject enrollment - 85% to 95% upon subject follow-up - 100% upon database lock and center closure [7] Group 5: Competitive Advantages - The company has established a comprehensive training system and SOPs to ensure effective management of personnel and projects [8] - Continuous updates to the quality control system help maintain project quality [9] - The company is expanding its clinical trial institution coverage through fundraising efforts [9]

普蕊斯（上海）医药科技开发股份有限公司 2022 年第三季度报告 证券代码：301257 证券简称：普蕊斯 公告编号：2022-034 普蕊斯（上海）医药科技开发股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 普蕊斯（上海）医药科技开发股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 156,176 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20% compared to RMB 83.33 million in the same period of 2021[1]. - The net profit attributable to shareholders for the first half of 2022 was RMB 15 million, up 25% from RMB 12 million in the same period last year[1]. - The company anticipates a revenue target of RMB 250 million for the full year 2022, representing a 25% increase from 2021[1]. - The company's operating revenue for the reporting period was ¥245,072,252.46, representing a 9.09% increase compared to ¥224,649,140.95 in the same period last year[22]. - The net profit attributable to shareholders was ¥19,425,727.28, a decrease of 28.93% from ¥27,333,730.39 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥17,481,139.36, down 35.91% from ¥27,274,068.12 year-on-year[22]. - The company reported a total revenue of 318.85 million RMB for the first half of 2022[69]. - The total revenue for the first half of 2022 was 168 million RMB, representing a 30% increase compared to the same period last year[190]. - The net profit attributable to shareholders for the first half of 2022 was 45 million RMB, with a profit margin of approximately 26.8%[191]. - The total comprehensive income for the first half of 2022 was CNY 19,425,727.28, down from CNY 27,333,730.39 in the same period of 2021[174]. Investment and Development - The company is investing RMB 10 million in new product development, focusing on antibody-drug conjugates and CAR-T therapies, with expected completion by Q4 2023[1]. - The company plans to invest 615.3 million RMB in new product development and market expansion initiatives in the upcoming year[191]. - The company has allocated 71.63 million RMB for research and development of new technologies in the current fiscal year[193]. - The company is focused on building a comprehensive big data platform to connect sponsors, researchers, patients, and clinical trial institutions[45]. - The company has initiated research and development for new technologies aimed at improving product efficacy and safety[196]. Market Expansion and Strategy - The company plans to expand its market presence by increasing its clinical trial services, targeting a 30% growth in user engagement by the end of 2023[1]. - The company aims to enhance its core service capabilities and expand brand awareness to increase market share in the SMO sector[45]. - The company is exploring potential mergers and acquisitions to strengthen its portfolio, with a budget of RMB 50 million allocated for this purpose[1]. - The company is exploring potential mergers and acquisitions to accelerate its growth strategy in the pharmaceutical sector[188]. - The company aims to expand its market presence by entering two new regions by the end of 2023, targeting a 15% increase in market share[190]. Operational Efficiency - The company aims to enhance its operational efficiency by implementing new technologies, expecting a 15% reduction in operational costs by mid-2023[1]. - The company has established a robust standard operating procedure (SOP) system with over 160 documents to ensure operational efficiency and quality management[35]. - The company has developed core technologies, including a project management system and SOP processes, but must continuously upgrade these technologies to meet industry trends and client needs[91]. - The company has established a standardized project management system that enhances the efficiency of clinical trial execution, ensuring stability and reliability in service delivery[49]. Risk Management - The company has identified key risks including regulatory changes and market competition, and has developed strategies to mitigate these risks[1]. - The company is facing risks related to declining gross margins[80]. - The company's gross profit margin is influenced by project execution quantity, scale, and compensation levels, with risks of margin decline due to market competition and cost control challenges[81]. - The execution cycle of project contracts is long, posing risks of revenue deviation due to potential delays or early terminations of clinical trial contracts[85]. - The company faces risks related to employee turnover, which could hinder business expansion and project execution, necessitating higher compensation and benefits to retain talent[89]. Human Resources and Employee Welfare - The company has a talent pool of over 3,450 professionals, serving more than 740 clinical trial institutions across over 160 cities in China[51]. - The company has established a comprehensive training system to ensure the professional development of its employees, which supports rapid talent replication and reliable clinical trial execution[54]. - The company has added 250 new job positions during the pandemic, adhering to a policy of no layoffs and no salary reductions[115]. - The company has optimized its human resources management system and innovated its incentive mechanisms to boost employee motivation[113]. - The company has maintained a commitment to social responsibility by supporting employees during the pandemic and ensuring business continuity[115]. Financial Position and Assets - Total assets at the end of the reporting period reached ¥1,019,311,239.59, an increase of 152.15% from ¥404,248,815.63 at the end of the previous year[22]. - The net assets attributable to shareholders increased by 283.95% to ¥878,636,422.92 from ¥228,843,138.26 at the end of the previous year[22]. - The total amount of raised funds was ¥702,000,000.00, with a net amount of ¥630,367,557.38 after deducting issuance costs[66]. - The company has not faced any environmental penalties and does not engage in activities that involve significant pollution[109]. - The company’s total assets at the end of the reporting period amounted to 123.4 million RMB, with a total liability of 54.28 million RMB[195]. Shareholder Information - The company completed its initial public offering (IPO) on May 17, 2022, issuing 15 million shares, increasing total shares from 45 million to 60 million[146]. - The total number of shares after the IPO is 60 million, with 15 million shares being unrestricted and 45 million shares subject to restrictions[147]. - The company’s shareholding structure includes 87.4% held by domestic legal entities and 12.6% held by domestic individuals[145]. - The company’s major shareholders include Shihezi Xitai with 11,364,210 restricted shares and Guanyu Zhaotai with 7,245,000 restricted shares[149]. - The company’s restricted shares have a lock-up period of 12 to 36 months, with some set to be released on May 17, 2023, and others on May 19, 2025[150].